Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Multiple myeloma is an incurable malignant disease which evnetuelly will relapse after
primary treatment. Clonal B-cells have been identified and in theory these cells might be
sleeping during primary treatment and be responsible for later relapse. Fluarabine has
documented effect on both resting and dividing cells including B-cells. The protocol aim at
evaluating safety and toxicity of adding fludarabine to induction chemotherapy with
cyclophosphamide and dexamethasone before high-dose melphalan with autologous stem cell
support.